Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 13

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 13
---
 for that nominee will instead be voted for the election of a substitute nominee proposed by the Board. Each person nominated for election has agreed to be named in this Proxy Statement and to serve if elected. Our management has no reason to believe that the nominees will be unable to serve.

INFORMATION REGARDING DIRECTOR NOMINEES AND CURRENT DIRECTORS The following is a brief biography of each nominee for director and a discussion of the specific experience, qualifications, attributes or skills of each nominee that led the Nominating and Corporate Governance Committee to recommend that person as a nominee for director, as of the date of this Proxy Statement:

| ​                    | ​ |   ​ | ​ | ​                                               |
| Name                 |   | Age |   | Principal Occupation/                           
 Position Held With the Company                  |
| Gene Mack            | ​ |  51 | ​ | President, Chief Executive Officer and Director |
| Khalid Islam, Ph.D.  | ​ |  69 | ​ | Founder and Chairman of the Board               |
| Dov Goldstein, M.D.  | ​ |  57 | ​ | Director                                        |
| Hans Peter Hasler    | ​ |  69 | ​ | Director                                        |
| Gwen Melincoff       | ​ |  73 | ​ | Director                                        |
| Claude Nicaise, M.D. | ​ |  72 | ​ | Director                                        |
| Eric I. Richman      | ​ |  64 | ​ | Director                                        |
| Jeffrey Riley        | ​ |  62 | ​ | Director                                        |

NOMINEES FOR ELECTION AT THE 2025 ANNUAL MEETING OF STOCKHOLDERS Gene Mackhas served as our Chief Executive Officer and director since January 2025. Prior to that, Mr. Mack was our Interim Chief Executive Officer and Chief Financial Officer from June 2024 after joining the Company as our Chief Financial Officer (“CFO”) in April 2024. Prior to joining the Company, Mr. Mack was CFO of privately held Imcyse SA from October of 2021 to October of 2023. Prior to Imcyse, Gene was CFO at OncoC4 until September 2021, a privately held biotechnology company that spun out of Merck & Co’s (MSD) $475 million acquisition of OncoImmune in 2020 where he had also been CFO since September 2020. From May of 2019 to September 2020, Mr. Mack